

4DMedical completes A\$5.5m Placement and launches A\$7m underwritten SPP

Not for release to US wire services or distribution in the United States

21 February 2025

Highlights

- 4DMedical receives commitments for \$5.5m via a Placement at A\$0.425 per share
- Strong support from new and existing institutional investors in Australia and offshore
- Proceeds from the Placement will be applied towards commercialisation requirements and for general working capital
- The Company will also offer a Share Purchase Plan (**SPP**) which is underwritten to A\$7m, with the Company reserving the ability to accept oversubscriptions under the SPP
- Subject to receiving shareholder approval, each participant in the Placement and SPP will also receive 1 unlisted attaching option, exercisable at A\$0.55, for each share issued under the Placement and SPP (**New Option**)
- Upon exercise of the New Options, the holder will receive one ordinary share and one piggyback option exercisable at A\$0.75, which the Company seeks to apply for official quotation (**Piggyback Option**)
- The issue of New Options and Piggyback Options in connection with the Placement and SPP will be subject to the Company obtaining shareholder approval at an EGM, which 4DMedical intends to convene on or around Thursday, 1 May 2025
- 4DMedical also intends to issue 5,000,000 New Options to sub-underwriters that have supported the SPP
- The Company will hold a webinar at 10.30am AEDT, Friday 21 February 2025

Melbourne, Australia, 21 February 2025: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces it has completed a share placement (**Placement**) to institutional and sophisticated investors. The Placement will raise approximately A\$5.5 million in gross proceeds.

The Placement will result in the issue of approximately 12.9 million shares at A\$0.425 per share (**Placement Shares**), within the Company’s existing placement capacity under ASX Listing Rules 7.1 and 7.1A. The issue price represents a 22.7% discount to the last closing price on 20 February 2025, being the last day the Company traded prior to the Placement.

In addition to the Placement, the Company will also offer Eligible Shareholders in Australia and New Zealand the opportunity to participate in a Share Purchase Plan (**SPP**). Eligible Shareholders will be entitled to apply for up to A\$30,000 of new shares, targeting an additional A\$7 million in gross proceeds.



Eligible Shareholders are those shareholders who:

- have a registered address in Australia or New Zealand as at 5.00pm (AEDT) on Thursday, 20 February 2025 (**Record Date**); and
- are not in the United States or acting for the account or benefit of a person in the United States.

The SPP will allow Eligible Shareholders to purchase between \$1,000 and \$30,000 worth of New Shares at an offer price being the lower of:

- A\$0.425 per share; and
- a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent.

The offer to acquire shares under the SPP opens on Tuesday, 25 February 2025 and will close on Tuesday, 18 March 2025. The Company reserves the right to close the offer early and/or to accept oversubscriptions of shares under the SPP, subject to the ASX Listing Rules and the *Corporations Act 2001*.

New shares issued under the Placement and SPP will have one unlisted free attaching option (**New Option**) for every 1 new share issued, with an exercise price of A\$0.55 and an expiry date on the earlier of 28 February 2026 and the date being 30 days from the date on which the Company announces receipt of FDA clearance for its ventilation and perfusion technology, CT:VQ™ (if at all) (**FDA Announcement**).

Upon their exercise, holders of New Options will receive 1 fully paid ordinary share and 1 further piggyback option for nil consideration (**Piggyback Option**), which will be exercisable at \$0.75 per Piggyback Option and expire on the earlier of 29 February 2028 and the date being 2 years from the date of the FDA Announcement.

The New Options and Piggyback Options proposed to be issued to participants under the Placement and the SPP will be issued subject to shareholder approval for the purpose of ASX Listing Rule 7.1.

Bell Potter Securities Limited is acting as Lead Manager to the Placement and SPP, and as Underwriter to the SPP. The SPP is underwritten to the value of \$7 million. The Company has also agreed to issue 5,000,000 New Options to sub-underwriters who have agreed to support the SPP (**Sub-Underwriter Options**).

Further details in relation to the SPP, including the scale-back policy, will be provided to Eligible Shareholders in a SPP Offer Booklet while the offer of the New Options, Piggyback Options and Sub-Underwriter Options will be undertaken pursuant to a transaction-specific prospectus.

Webinar

The Company will hold an investor webinar at 10.30AM AEDT, Friday, 21 February 2025. Please refer to the details in the Investor Webinar announcement.

4DMedical Founder and CEO Andreas Fouras said:

Following FDA clearance of our first product XV LVAS® about 4½ years ago, the 4DMedical team worked tirelessly to take that product to market. The following 2 years taught us a lot about what is needed to transform lung health: a comprehensive portfolio, streamlined reports and simple processes to connect our products to healthcare IT systems.

With that hard-fought knowledge in hand, we have solved for each of these elements and the results are now becoming clearly visible on our top line: we are experiencing strong growth in the number of sites, the number of scans per site and the revenue earned per scan. In 2 short years, our sales team of 10 has built



SaaS revenues from nothing to a run rate greater than \$6m. The full might and scale of the Philips sales team will provide another layer of growth to our organic growth.

Later in the year, as CT:VQ™ comes online, we gain yet another dramatic catalyst for growth. CT:VQ™ is set to disrupt a billion dollar segment of respiratory diagnostics by displacing Nuclear VQ imaging with a technology that is faster, safer, cheaper, more convenient and more accessible.

I look forward to keeping you informed of our progress in what is shaping up to be the transformational year we have all been looking for.

Key dates for capital raising

Bell Potter Securities Limited is sole Lead Manager and bookrunner to the Placement and SPP, and Underwriter to the SPP.

EVENT	TIMING (SYDNEY TIME)
SPP Record Date	Thursday, 20 February 2025
Announcement of Placement and SPP	Friday, 21 February 2025
Release of SPP offer booklet in relation to SPP Shares	Tuesday, 25 February 2025
Opening date for SPP Offer	
Settlement of Placement	Thursday, 27 February 2025
Allotment of New Shares under the Placement	Friday, 28 February 2025
Closing date for SPP Offer	Tuesday, 18 March 2025
Announce results of SPP Offer	Tuesday, 25 March 2025
Allotment of New Shares under the SPP Offer	Tuesday, 25 March 2025
Lodgement of Prospectus with ASIC and ASX in relation to New Options, Piggyback Options and Sub-Underwriter Options	Tuesday, 25 March 2025
Quotation of New Shares under the SPP Offer	Wednesday, 26 March 2025
Opening date for offer of New Options, Piggyback Options and Sub-Underwriter Options	Tuesday, 1 April 2025
Notice of EGM lodged	Tuesday, 1 April 2025
EGM held to approve issue of New Options and Piggyback Options	Thursday, 1 May 2025
Issue of New Options, Piggyback Options and Sub-Underwriter Options	Friday, 2 May 2025

For personal use only



This timetable is indicative only and subject to change. The Company reserves the right to amend the dates at its discretion and without notice, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth).

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

-ENDS-

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of Imbio, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit www.4dmedical.com